Experiences with the new antibiotic gentamicin.
D000667:Ampicillin / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001419:Bacteria / Q000187:drug effects*; D002056:Burns / Q000188:drug therapy; D002512:Cephalothin / Q000494:pharmacology; D056486:Chemical and Drug Induced Liver Injury; D002701:Chloramphenicol / Q000494:pharmacology; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects; D005839:Gentamicins / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D007674:Kidney Diseases / Q000139:chemically induced; D007759:Labyrinth Diseases / Q000139:chemically induced; D009355:Neomycin / Q000009:adverse effects; D011014:Pneumonia / Q000188:drug therapy; D011113:Polymyxins / Q000494:pharmacology; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D011704:Pyelonephritis / Q000188:drug therapy; D012293:Rifampin / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D013752:Tetracycline / Q000494:pharmacology; D014076:Tooth Diseases / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D011113:Polymyxins; D002701:Chloramphenicol; D000667:Ampicillin; D013752:Tetracycline; D009355:Neomycin; D002512:Cephalothin; D012293:Rifampin